Device Trial Radar · NCT07323251
Clinical Study on the Effectiveness of Diverse Segments Defocus Optimization in Spectacle Lenses for Slowing Myopia Progression
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
May 19, 2023
Primary completion
Jun 1, 2025
Study completion Nov 16, 2026
Sponsor
- Lead sponsor
- Beijing Tongren HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 7, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 7 years, up to 15 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Clinical Trial The goal of this clinical trial is to evaluate the effectiveness of two types of Diverse Segments Defocus Optimization (D.S.D.O.) spectacle lenses in slowing myopia progression in children. It will also assess the safety of these lenses. The main questions it aims to answer are: Do D.S.D.O. lenses reduce the progression of myopia as measured by changes in cycloplegic refraction and axial length? What adverse events do participants experience when wearing D.S.D.O. lenses? Researchers will compare two optical designs of D.S.D.O. lenses (Intervention Group1: Design 1; Intervention Group2: Design 2) to determine their relative efficacy in controlling myopia progression. Participants will: Wear assigned D.S.D.O. lenses daily for 12 months (except during sleep or unavoidable situations). Attend clinic visits at baseline, 3, 6, 9, and 12 months for comprehensive eye examinations. Maintain a diary recording daily wear time, visual symptoms, and any adverse events.
Conditions
- Children With Myopia
- Treatment
- Multizone Lens Design for Myopic Defocus
- Visual Quality
- Efficacy
Interventions
Diverse Segments Defocus Optimization (D.S.D.O.) spectacle lensesDevice
This clinical trial employs a randomized, parallel-group, superiority design to evaluate two novel optical designs of Diverse Segments Defocus Optimization (D.S.D.O.) myopia management spectacle lenses. A total of 120 myopic Chinese children, aged 7 to 15 years, will be recruited and randomly assigned in a 1:1 ratio to one of two intervention groups. Both groups will receive myopia control spectacles: the PD Group will use lenses with peripheral microlens arrays, and the DCDD Group will use lenses combining identical microlens architecture with light-scattering dot elements. Participants are required to wear the assigned spectacles daily for the entire 12-month study duration, except during sleep or other unavoidable circumstances. These spectacles provide full refractive correction while incorporating defocus and contrast reduction to slow myopia progression.The study includes a baseline visit, a dispensing visit, and follow-up assessments at 3, 6, 9, and 12 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Spherical Equivalent Refraction (SER)Time frame: From enrollment to the end of treatment at 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tongren Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.